Moors & Cabot Inc. Buys 198 Shares of Zimmer Biomet Holdings Inc (NYSE:ZBH)

Moors & Cabot Inc. lifted its stake in Zimmer Biomet Holdings Inc (NYSE:ZBH) by 7.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,811 shares of the medical equipment provider’s stock after buying an additional 198 shares during the period. Moors & Cabot Inc.’s holdings in Zimmer Biomet were worth $389,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. One Capital Management LLC acquired a new stake in shares of Zimmer Biomet during the third quarter worth approximately $229,000. Ballentine Partners LLC increased its holdings in shares of Zimmer Biomet by 9.5% during the third quarter. Ballentine Partners LLC now owns 2,590 shares of the medical equipment provider’s stock worth $355,000 after buying an additional 225 shares in the last quarter. Boston Trust Walden Corp increased its holdings in shares of Zimmer Biomet by 6.9% during the third quarter. Boston Trust Walden Corp now owns 51,465 shares of the medical equipment provider’s stock worth $7,064,000 after buying an additional 3,330 shares in the last quarter. Calamos Advisors LLC increased its holdings in shares of Zimmer Biomet by 9.5% during the third quarter. Calamos Advisors LLC now owns 50,159 shares of the medical equipment provider’s stock worth $6,885,000 after buying an additional 4,350 shares in the last quarter. Finally, Strs Ohio increased its holdings in shares of Zimmer Biomet by 3.8% during the third quarter. Strs Ohio now owns 10,327 shares of the medical equipment provider’s stock worth $1,417,000 after buying an additional 376 shares in the last quarter. Hedge funds and other institutional investors own 87.81% of the company’s stock.

In related news, insider Didier Deltort sold 360 shares of the firm’s stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $139.25, for a total value of $50,130.00. Following the completion of the sale, the insider now owns 1,194 shares of the company’s stock, valued at $166,264.50. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Chad F. Phipps sold 7,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 29th. The shares were sold at an average price of $138.28, for a total transaction of $967,960.00. Following the completion of the transaction, the vice president now directly owns 37,722 shares in the company, valued at $5,216,198.16. The disclosure for this sale can be found here. In the last three months, insiders sold 40,391 shares of company stock valued at $5,642,274. 0.72% of the stock is currently owned by company insiders.

Several analysts have recently weighed in on ZBH shares. Wells Fargo & Co raised their price objective on shares of Zimmer Biomet from $150.00 to $158.00 and gave the stock an “outperform” rating in a report on Monday, September 9th. BTIG Research raised shares of Zimmer Biomet from a “neutral” rating to a “buy” rating and set a $158.00 price objective for the company in a report on Monday, October 7th. Argus raised shares of Zimmer Biomet from a “hold” rating to a “buy” rating and set a $160.00 price objective for the company in a report on Monday, August 12th. Citigroup raised their price objective on shares of Zimmer Biomet from $146.00 to $158.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. Finally, Robert W. Baird raised shares of Zimmer Biomet from a “neutral” rating to an “outperform” rating and raised their price objective for the stock from $132.00 to $154.00 in a report on Monday, July 29th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and nineteen have issued a buy rating to the stock. Zimmer Biomet has a consensus rating of “Buy” and an average target price of $145.40.

Shares of Zimmer Biomet stock opened at $134.89 on Friday. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.19 and a quick ratio of 0.56. The firm has a market cap of $27.68 billion, a P/E ratio of 17.66, a P/E/G ratio of 2.56 and a beta of 1.16. The firm has a 50 day simple moving average of $137.15 and a 200 day simple moving average of $127.77. Zimmer Biomet Holdings Inc has a fifty-two week low of $96.99 and a fifty-two week high of $143.57.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Friday, July 26th. The medical equipment provider reported $1.93 earnings per share for the quarter, beating analysts’ consensus estimates of $1.91 by $0.02. The business had revenue of $1.99 billion during the quarter, compared to analyst estimates of $1.98 billion. Zimmer Biomet had a negative net margin of 4.56% and a positive return on equity of 13.40%. Zimmer Biomet’s revenue for the quarter was down .9% compared to the same quarter last year. During the same quarter last year, the business posted $1.92 earnings per share. On average, sell-side analysts expect that Zimmer Biomet Holdings Inc will post 7.82 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 31st. Investors of record on Monday, September 30th will be issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.71%. The ex-dividend date is Friday, September 27th. Zimmer Biomet’s dividend payout ratio is currently 12.57%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.

Read More: What is an overbought condition?

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings Inc (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.